Q. An endangered tribe has developed a severe skeletal deformity. A university research has identified a mineral supplement as a possible remedy, though clinical trials are yet to be conducted. Should the District Magistrate (DM) use this research on the tribe? Discuss from the perspective of medical and administrative ethics.

Model Answer: 

The DM faces a conflict between administrative urgency (Articles 21 & 46) and bioethical non-maleficence (Primum non nocere). The DM should not administer the untested supplement directly.

Ethical Dilemmas: Medical vs. Administrative

• Medical Bioethics:
  • Non-Maleficence: Untested supplements risk toxicity, violating the Nuremberg Code and ICMR Bioethics Guidelines (2017).
  • Informed Consent: Cultural vulnerability and information asymmetry compromise autonomous consent, risking exploitation (Tuskegee study cautionary parallel).
• Administrative Ethics:
  • Rule of Law vs. Paternalism: Benevolent intent cannot bypass statutory validation mandates (Drugs and Cosmetics Act, 1940).
  • Fiduciary Duty of Care: Protecting endangered tribes requires evidence-based welfare over speculative administrative gambles.

Ethically Justified Course of Action

1. Provide Validated Relief: Deploy immediate palliative care and approved nutritional support to manage symptoms.
2. Fast-Track Approvals: Coordinate with ICMR and CDSCO for expedited clinical trials (New Drugs and Clinical Trials Rules, 2019).
3. Regulated Compassionate Access: Explore legal “Compassionate Use” provisions only after basic clinical safety is established.

Administrative empathy must harmonize with scientific rigor, ensuring tribal welfare without compromising constitutional morality and medical ethics.